Takeda Pharmaceutical Co. has revised the operational profit under the international accounting standards for the fiscal year ending March 2025 from 265 billion yen to 344 billion yen, on January 30,2025. It is estimated as 60.7% up from the previous year. They underscore that this decision has been made due to the impact of increased profits in the United States from Vyvanse which is used to treat attention-deficit hyperactivity disorder.
Takeda Pharmaceutical, a Japanese multinational company and it is one of the largest in the world which was founded in 1781. It focuses on the research and development in several key therapeutic areas, which includes gastroenterology, oncology, neuroscience, rare diseases and vaccines. Takeda is operated in 80 countries which has made it to become one of the world’s top ten pharmaceutical companies.
